Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative di... 11/04/2024 Healthcare Access to innovation Drug discovery Innovative drugs Personalized medicine Advanced therapies Parkinson's is an extremely debilitating disease, there is no cure, and we only have medications aimed at alleviating... AseBio
Biotechnology seeks solutions for Parkinson's, the second most common neurodegenerative di... 11/04/2024 Approximately 10,000 new cases of Parkinson's are detected each year in Spain, with a total figure exceeding 150,000... AseBio
The Role of Real-World Evidence in the Price and Reimbursement Decisions for Rare Diseases... 02/04/2024 Healthcare Rare diseases Innovative drugs Financing Real-world evidence (RWE) is a promising source of data that could help to accelerate drug access in rare diseases. Partners
Celtarys Research, USC-biofarma and ZeClinics seek new therapeutic targets for Parkinson's... 01/04/2024 Healthcare Access to innovation Drug discovery Innovative drugs Advanced therapies This project, coordinated by Asebio, brings together ZeClinics' target validation and in vivo drug screening... AseBio
Spanish biotechnology leads the global fight against tuberculosis 24/03/2024 Healthcare Access to innovation Innovative drugs On the occasion of World Tuberculosis Day, we delve into the advances achieved by the candidate vaccine against... AseBio - Zendal
Konexio Biotech, in the First Day of Inspection and Control of Medicines AEMPS & AEFI 22/03/2024 Healthcare Drug discovery Innovative drugs This Thursday, March 21, Konexio Biotech, represented by its CEO, Andrea Romero, participated in the 'First Day of... Partners - KONEXIO BIOTECH
Biotechnology to reduce the risk of kidney transplant failure and adverse events related t... 14/03/2024 Healthcare Innovative drugs Personalized medicine On the occasion of World Kidney Day, we interviewed Isabel Portero, founder and CEO of Biophope, a biotechnology company... AseBio - Biohope
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Tria... 28/02/2024 Healthcare Innovative drugs ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline... Partners - ARTHEx Biotech
Why and how to involve rare disease patients in the evaluation process of a new health tec... 27/02/2024 Healthcare Rare diseases Innovative drugs Personalized medicine Advanced therapies Alira Health experts explain in an interview the importance of involving patients with rare diseases in the evaluation... Partners
ORYZON reports financial results and corporate update for quarter ended December 31, 2023 27/02/2024 Healthcare Innovative drugs Personalized medicine Advanced therapies Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with... Partners - Oryzon Genomics
